With 0.63 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.68 million shares. The 52-week range on HCAT shows that it touched its highest point at $9.72 and its lowest point at $5.25 during that stretch. It currently has a 1-year price target of $9.79. Beta for the stock currently stands at 1.39.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of HCAT was down-trending over the past week, with a drop of -5.77%, but this was down by -6.77% over a month. Three-month performance dropped to -30.54% while six-month performance fell -25.82%. The stock lost -46.14% in the past year, while it has lost -26.03% so far this year. A look at the trailing 12-month EPS for HCAT yields -1.35 with Next year EPS estimates of 0.37. For the next quarter, that number is 0.07. This implies an EPS growth rate of 108.21% for this year and 17.49% for next year. EPS is expected to grow by 50.80% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 7.69%.
Float and Shares Shorts:
At present, 60.85 million HCAT shares are outstanding with a float of 58.54 million shares on hand for trading.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for HCAT since 11 analysts follow the stock currently. There are 8 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 3 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of $0.36909 being high and $0.25553 being low. For HCAT, this leads to a yearly average estimate of $0.31231. Based on analyst estimates, the high estimate for the next quarter is $0.15 and the low estimate is $0.03. The average estimate for the next quarter is thus $0.07.
